Who owns United Therapeutics (UTHR)? Superinvestor holders

4 superinvestors of the 157 tracked here hold United Therapeutics (UTHR) in their latest 13F filing, with $1.4B between them. Jim Simons (1938–2024) gives it the most weight: 1.24% of the reported portfolio. In their latest reported quarter, Ray Dalio (founder) and Israel Englander added; Jim Simons (1938–2024) and Baillie Gifford team reduced.

David Shaw (founder) sold out of it in their latest quarter.

Hold it now
4
of 157 tracked
Combined value
$1.4B
Bought / sold
2 / 3
last quarter

Key facts

Superinvestors holding it
4 of 157
Biggest holder
Jim Simons (1938–2024), $908.2M
Largest weight
Jim Simons (1938–2024), 1.24%of their portfolio
Combined value
$1.4B
Bought last quarter
2
Sold last quarter
3

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding UTHR, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1Jim Simons (1938–2024)Renaissance Technologies1.24%$908.2M1.68M▼ Reduced 1.9%−32.81KQ3 2026
2Ray Dalio (founder)Bridgewater Associates0.25%$60.3M111.33K▲ Added 0.1%+156Q2 2026
3Baillie Gifford teamBaillie Gifford & Co0.19%$205.4M379.1K▼ Reduced 19%−88.12KQ3 2026
4Israel EnglanderMillennium Management0.15%$221.6M409.07K▲ Added 167%+255.7KQ2 2026

Sold out last quarter

Quarter by quarter

Superinvestor ownership of UTHR by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 20269222.05M$1.1B02
Q2 202615752.96M$1.6B34
Q1 202615773.99M$2.4B43
Q4 202515764.07M$2B33
Q3 202515743.93M$1.6B15
Q2 202515764.54M$1.3B41
Q1 202515664.2M$1.3B32
Q4 202415664.14M$1.5B32

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of UTHR held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Jim Simons (1938–2024)1.68M1.71M1.79M1.91M2.17M2.12M2.11M2.09M
Baillie Gifford team379.1K467.21K428.13K323.02K————
Israel Englander·409.07K——————
Josef Lakonishok—268.37K398.67K408.07K686.71K864.62K902.32K908.72K
Ray Dalio (founder)·111.33K111.17K64.6K—195.12K193.78K107.73K
Cliff Asness·—826.23K1.28M986.48K1.27M908.45K975.44K
Ken Griffin·—360.64K—————
Joel Greenblatt·—80.39K80.02K80.96K89.4K89.34K61.18K
Andrew Spokes—————1K1K1K

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own UTHR?

In their latest 13F filings: Jim Simons (1938–2024) (1.24% of the portfolio, $908.2M), Ray Dalio (founder) (0.25% of the portfolio, $60.3M), Baillie Gifford team (0.19% of the portfolio, $205.4M), Israel Englander (0.15% of the portfolio, $221.6M).

Who bought UTHR last quarter?

Ray Dalio (founder) (added 0.1%), Israel Englander (added 167%). “Last quarter” is each investor's latest reported quarter.

Who sold UTHR last quarter?

Reduced: Jim Simons (1938–2024) (1.9% fewer shares), Baillie Gifford team (19% fewer shares). Sold out entirely: David Shaw (founder) (was $58.8M).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns United Therapeutics (UTHR)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/UTHR/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to UTHR by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.